UPC2 Is Universally Essential for Azole Antifungal Resistance in Candida albicans
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
In Candida albicans , the transcription factor Upc2 is central to the regulation of ergosterol biosynthesis. UPC2 -activating mutations contribute to azole resistance, whereas disruption increases azole susceptibility. In the present study, we investigated the relationship of UPC2 to fluconazole susceptibility, particularly in azole-resistant strains. In addition to the reduced fluconazole MIC previously observed with UPC2 disruption, we observed a lower minimum fungicidal concentration (MFC) for a upc2 Δ/Δ mutant than for its azole-susceptible parent, SC5314. Moreover, the upc2 Δ/Δ mutant was unable to grow on a solid medium containing 10 μg/ml fluconazole and exhibited increased susceptibility and a clear zone of inhibition by Etest. Time-kill analysis showed higher fungistatic activity against the upc2 Δ/Δ mutant than against SC5314. UPC2 disruption in strains carrying specific resistance mutations also resulted in reduced MICs and MFCs. UPC2 disruption in a highly azole resistant clinical isolate containing multiple resistance mechanisms likewise resulted in a reduced MIC and MFC. This mutant was unable to grow on a solid medium containing 10 μg/ml fluconazole and exhibited increased susceptibility and a clear zone of inhibition by Etest. Time-kill analysis showed increased fungistatic activity against the upc2 Δ/Δ mutant in the resistant background. Microarray analysis showed attenuated induction by fluconazole of genes involved in sterol biosynthesis, iron transport, or iron homeostasis in the absence of UPC2 . Taken together, these data demonstrate that the UPC2 transcriptional network is universally essential for azole resistance in C. albicans and represents an attractive target for enhancing azole antifungal activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“UPC2, which encodes a major transcriptional regulator of ergosterol biosynthesis 54 , affected both RAD and FoG levels significantly, while two regulators of efflux pump transcription had no significant effect, consistent with the redundancy of efflux mechanisms 55 (Fig. 4e).”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [54]
In the citing paper
“Upc2 is a global ergosterol-synthesis-related gene regulator contributing to FLC tolerance [40,41].”
From Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species (2024) · cites this paper as [40]
In the citing paper
“Vasicek et al. reported that activation of Upc2 induces azole resistance in C. albicans, whereas dysfunction of Upc2 enhances the sensitivity of C. albicans to azoles [15].”
From Disruption of the UPC2 Gene Enhances Fluconazole Antifungal Activity by Inhibiting HAC1 mRNA Splicing in Candida albicans (2026) · cites this paper as [15]
In the citing paper
“Similarly, pitavastatin interacted synergistically with fluconazole against C. albicans SC-TAC1G980E strain, which has a gain of function mutation in TAC1, a positive transcription regulator for the ABC (ATP Binding Cassette) membrane transporters29–31.”
From Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species (2020) · cites this paper as [30]
In the citing paper
“However, the pitavastatin-fluconazole combination failed to display similar interactions against strain TWO7241, which exhibits increased mRNA levels of both ERG11 and MDR1, and strain SC-MRR1P683S which has a gain of function mutation in MRR1, a positive transcription regulator for the MFS (Major Facilitator Superfamily) membrane transporters29–31.”
From Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species (2020) · cites this paper as [30]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,785 · cited 1×
“Integration of these sterols into the plasma membrane disrupts its integrity, resulting in its altered structure and function (12, 43, 44).”
BackgroundClinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353 · cited 1×
“Currently known mechanisms of resistance to the azoles include alterations in the expression of drug efflux pump (CDR1, CDR2, and MDR1) and ergosterol biosynthesis (ERG) genes and mutations in ERG11 (18).”
BackgroundA rapid and simple method for preparation of RNA from Saccharomyces cerevisiae
Schmitt, M. E., Brown, T. A., & Trumpower, B. L. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.10.3091 · Cited by 1,338
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Cell Wall Integrity Signaling in Saccharomyces cerevisiae
Levin, D. E. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.2.262-291.2005 · Cited by 1,136 · cited 1×
“compromised host, the fungistatic nature of fluconazole limits its efficacy against Candida species (14, 15).”
BackgroundReference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Klein, R. S., Harris, C. A., Small, C. B., Moll, B., Lesser, M., & Friedland, G. H. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408093110602 · Cited by 863
The SAT1 flipper, an optimized tool for gene disruption in Candida albicans
Reuß, O., Vik, Å., Kolter, R., & Morschhäuser, J. (2004) · Gene · doi:10.1016/j.gene.2004.06.021 · Cited by 742 · cited 3×
“Plasmid pSFS2 contains the entire SAT1-flipper cassette (24).”
BackgroundMethodInfluentialEpidemiology of Nosocomial Fungal Infections, with Emphasis on Candida Species
Jarvis, W. R. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1526 · Cited by 636
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Antifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Resistance Mechanisms in Clinical Isolates of Candida albicans
White, T. C., Holleman, S., Dy, F., Mirels, L. F., & Stevens, D. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1704-1713.2002 · Cited by 461 · cited 1×
“We constructed upc2 / mutant strains in the background of an azole-resistant clinical isolate (isolate 12-99) known to carry four of the most common mechanisms of azole resistance: overexpression of CDR1 and CDR2, overexpression of MDR1, overexpression of ERG11, and a mutation in ERG11 (35).”
BackgroundCoste, A. T., Karababa, M., Ischer, F., Bille, J., & Sanglard, D. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1639-1652.2004 · Cited by 407
Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382
Evolution of antifungal-drug resistance: mechanisms and pathogen fitness
Anderson, J. B. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1179 · Cited by 375
Morschhäuser, J., Barker, K. S., Liu, T. T., Blaß-Warmuth, J., Homayouni, R., & Rogers, P. D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030164 · Cited by 355
Self-citationPfaller, M. A., Sheehan, D. J., & Rex, J. H. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.268-280.2004 · Cited by 352
Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351 · cited 1×
“Integration of these sterols into the plasma membrane disrupts its integrity, resulting in its altered structure and function (12, 43, 44).”
BackgroundKelly, S. L., Lamb, D. C., Corran, A. J., Baldwin, B. C., & Kelly, D. E. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1272 · Cited by 296
Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J., & Pfaller, M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.2.240 · Cited by 269
Ruhnke, M., Eigler, A., Tennagen, I., Geiseler, B., Engelmann, E., & Trautmann, M. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.9.2092-2098.1994 · Cited by 251 · cited 3×
“C. albicans exhibits inhibited growth in the presence of this fungistatic drug, and it is generally believed that such fungistatic activity facilitates the development of resistance, creating problems for treatment, especially in immunocompromised patients with OPC (16, 17).”
BackgroundKlepser, M. E., Wolfe, E. J., Jones, R. N., Nightingale, C. H., & Pfaller, M. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1392 · Cited by 245 · cited 1×
“CFU were counted in duplicate after 48 h at 35°C and were plotted on a log-scale curve versus time (23).”
MethodFlowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D. (2012) · Eukaryotic Cell · doi:10.1128/ec.00215-12 · Cited by 239 · cited 5×
“In the presence of fluconazole, the ERG11 gene product, lanosterol demethylase, is inhibited, leading to the accumulation of toxic sterol precursors and the production of alternate sterols, such as lanosterol, eburicol, obtusifoliol, 14 -methyl fecosterol, and 14 -methylergosta-8,24(28)-dien-3 ,6 -diol (21).”
BackgroundMethodInfluentialSelf-citationMacPherson, S., Akache, B., Weber, S., De Deken, X., Raymond, M., & Turcotte, B. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1745-1752.2005 · Cited by 238 · cited 3×
“albicans, showing that azole-inducible expression of ERG2, ERG7, ERG11, and ERG25 is diminished in the absence of UPC2 (19, 36).”
BackgroundFeigal, D. W., Katz, M. H., Greenspan, D., Westenhouse, J., Winkelstein, W., Lang, W., Samuel, M., Buchbinder, S. P., Hessol, N. A., Lifson, A. R., et al. (1991) · AIDS · doi:10.1097/00002030-199105000-00007 · Cited by 237
Dunkel, N., Liu, T. T., Barker, K. S., Homayouni, R., Morschhäuser, J., & Rogers, P. D. (2008) · Eukaryotic Cell · doi:10.1128/ec.00103-08 · Cited by 236
Self-citationUpregulation of ERG Genes in Candida Species by Azoles and Other Sterol Biosynthesis Inhibitors
Henry, K. W., Nickels, J. T., & Edlind, T. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2693-2700.2000 · Cited by 216 · cited 1×
“Fluconazole treatment also induces the expression of ERG11 and other genes of the ergosterol biosynthesis pathway, leading to increased production not only of lanosterol demethylase but also of enzymes involved in alternate sterol production (46).”
BackgroundRole of Candida albicans Transcription Factor Upc2p in Drug Resistance and Sterol Metabolism
Silver, P. M., Oliver, B. G., & White, T. C. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1391-1397.2004 · Cited by 216 · cited 2×
“albicans, showing that azole-inducible expression of ERG2, ERG7, ERG11, and ERG25 is diminished in the absence of UPC2 (19, 36).”
BackgroundWatson, P. F., Rose, M. E., Ellis, S. W., England, H., & Kelly, S. L. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91792-0 · Cited by 197 · cited 1×
“Under these conditions, growth is inhibited but the organism remains viable (45).”
BackgroundIdentification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans
Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Rolley, N., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00348-10 · Cited by 168
Rogers, P. D., & Barker, K. S. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1220-1227.2003 · Cited by 157
Self-citationPrasad, T., Chandra, A., Mukhopadhyay, C. K., & Prasad, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00653-06 · Cited by 149 · cited 1×
“observed that an ftr1 / mutant, defective in high-affinity iron uptake, also exhibited enhanced susceptibility to fluconazole (47).”
BackgroundKuipers, M. E., de Vries, H. G., Eikelboom, M. C., Meijer, D. K. F., & Swart, P. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2635 · Cited by 148
Heilmann, C. J., Schneider, S., Barker, K. S., Rogers, P. D., & Morschhäuser, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-09 · Cited by 142
Self-citationSchubert, S., Barker, K. S., Znaidi, S., Schneider, S., Dierolf, F., Dunkel, N., Aïd, M., Boucher, G., Rogers, P. D., Raymond, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01343-10 · Cited by 135 · cited 3×
“This trend in susceptibility is consistent with what has been observed previously for this MRR1upc2 / mutant (20).”
BackgroundResultSelf-citationZnaidi, S., Weber, S., Zin Al-Abdin, O., Bomme, P., Saidane, S., Drouin, S., Lemieux, S., De Deken, X., Robert, F., & Raymond, M. (2008) · Eukaryotic Cell · doi:10.1128/ec.00070-08 · Cited by 119 · cited 4×
“albicans, Upc2 binds to the promoters of CDR1 and MDR1 and can regulate their expression (29).”
BackgroundMethodInfluentialSussman, A., Huss, K., Chio, L.-C., Heidler, S., Shaw, M., Ma, D., Zhu, G., Campbell, R. M., Park, T.-S., Kulanthaivel, P., et al. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.4.932-943.2004 · Cited by 111
Hoot, S. J., Smith, A. R., Brown, R. P., & White, T. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00995-10 · Cited by 107
Pharmacotherapy : Principles and Practice
Chisholm‐Burns, M. A. (2008) · Cited by 103
Sasse, C., Dunkel, N., Schäfer, T., Schneider, S., Dierolf, F., Ohlsen, K., & Morschhäuser, J. (2012) · Molecular Microbiology · doi:10.1111/j.1365-2958.2012.08210.x · Cited by 93 · cited 1×
“It has been shown recently that the constructed MRR1 and TAC1 mutants exhibit a fitness defect associated with the introduction of these specific resistance mutations, whereas clinical isolates carrying such mutations appear to have regained fitness (42).”
BackgroundSasse, C., Schillig, R., Dierolf, F., Weyler, M., Schneider, S., Mogavero, S., Rogers, P. D., & Morschhäuser, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025623 · Cited by 61
Self-citationGenetic basis of antifungal drug resistance
Marie, C., & White, T. C. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0021-y · Cited by 57
Venkatesh, M. P., & Rong, L. (2008) · Journal of Medical Microbiology · doi:10.1099/jmm.0.2008/001263-0 · Cited by 57
Kim, J., Cho, Y.-J., Do, E., Choi, J., Hu, G., Cadieux, B., Chun, J., Lee, Y., Kronstad, J. W., & Jung, W. H. (2012) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2012.08.006 · Cited by 53 · cited 1×
“A similar observation has been made for Cryptococcus neoformans, where disruption of the genes encoding the ferroxidase (CFO1) and an iron permease (CFT1) of the high-affinity reductive iron uptake system resulted in increased susceptibility to azole antifungals (52).”
ResultOliver, B. G., Song, J. L., Choiniere, J. H., & White, T. C. (2007) · Eukaryotic Cell · doi:10.1128/ec.00331-06 · Cited by 53 · cited 1×
“UPC2 has been well characterized with regard to its impact on fluconazole susceptibility and its role in regulating genes of the ergosterol biosynthesis pathway (19, 29, 36, 37).”
BackgroundCandida Resistance and Its Clinical Relevance
Klepser, M. E. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.6part2.68s · Cited by 46
Schubert, S., Popp, C., Rogers, P. D., & Morschhäuser, J. (2011) · Eukaryotic Cell · doi:10.1128/ec.05100-11 · Cited by 39
Self-citationResistance and tolerance mechanisms to antifungal drugs in fungal pathogens
Sanglard, D. (2003) · Mycologist · doi:10.1017/s0269915x03002076 · Cited by 37 · cited 3×
“C. albicans exhibits inhibited growth in the presence of this fungistatic drug, and it is generally believed that such fungistatic activity facilitates the development of resistance, creating problems for treatment, especially in immunocompromised patients with OPC (16, 17).”
BackgroundClinical characteristics and management responses in 85 HIV-infected patients with oral candidiasis
Silverman, S., Gallo, J., McKnight, M. L., Mayer, P., deSanz, S., & Tan, M. M. (1996) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/s1079-2104(96)80304-0 · Cited by 36
Candida infection in HIV positive patients 1985–2007
Traeder, C., Kowoll, S., & Arastéh, K. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01574.x · Cited by 29
Kuipers, M. E., Beljaars, L., Van Beek, N., De Vries, H. G., Heegsma, J., Van Den Berg, J. J. M., Meijer, D. K. F., & Swart, P. J. (2002) · APMIS · doi:10.1034/j.1600-0463.2002.100403.x · Cited by 20
Cutaneous Antifungal Agents: Selected Compounds in Clinical Practice and Development
Elewski, B. E. (1994) · Archives of Dermatology · doi:10.1001/archderm.1994.01690050139030 · Cited by 20
Isolation of Yeast Genomic DNA for Southern Blot AnalysisPreprint
Amberg, D. C., Burke, D. J., & Strathern, J. N. (2006) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot4149 · Cited by 16 · cited 1×
“Genomic DNA was isolated as described previously (26).”
Method
Cited by
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Regulation of Ergosterol Biosynthesis in Saccharomyces cerevisiae
Jordá, T., & Puig, S. (2020) · Genes · doi:10.3390/genes11070795 · Cited by 489
“albicans sensitivity to azole treatments, even in highly azole resistant clinical isolates containing multiple resistance mechanisms [70,77].”
BackgroundRosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270
The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors
Zhang, J., Li, L., Lv, Q., Yan, L., Wang, Y., & Jiang, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00691 · Cited by 245
“glabrata is deleted, the susceptibility to azoles will be enhanced (Guida et al., 2011; Vasicek et al., 2014; Whaley et al., 2014).”
BackgroundStructural mechanism of ergosterol regulation by fungal sterol transcription factor Upc2
Yang, H., Tong, J., Lee, C. W., Ha, S., Eom, S. H., & Im, Y. J. (2015) · Nature Communications · doi:10.1038/ncomms7129 · Cited by 223
Metadata
- Authors
- Vasicek, E. M., Berkow, E. L., Flowers, S. A., Barker, K. S., & Rogers, P. D.
- Affiliations
- University of Tennessee Health Science Center (US)
- Venue
- Eukaryotic Cell
- Publisher
- American Society for Microbiology
- Published
- 2014-07
- Volume
- 13
- Issue
- 7
- Pages
- 933-946
- ISSN
- 1535-9778 (ISSN-L)
- 1535-9786
- PMC
- PMC4135735
- OpenAlex
- W2046705160
- Cited by
- 71
- References
- 53
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 6 · 2019: 8 · 2018: 5 · 2017: 3 · 2016: 3 · 2015: 4 · 2014: 2
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Eukaryotic Cell (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI058145)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, azole resistance, fluconazole susceptibility, ergosterol biosynthesis, minimum fungicidal concentration, fungistatic activity, iron homeostasis, iron transport genes, antifungal drug targets
- MeSH terms
- Antifungal Agents, Candida albicans, Fungal Proteins, Transcription Factors, Fluconazole, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.